{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-001929","form_type":"8-K","ticker":null,"cik":"0001923840","company_name":"Third Harmonic Bio, Inc.","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.318804+00:00","generated_at":"2026-06-07T04:17:58.787851+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"THRD appoints new CFO, provides THB335 update; IND filing on track for H1 2024","bullets":["Christopher M. Murphy appointed CFO and Business Officer effective Jan 4, 2024; base salary $495K, annual bonus up to 40%, option for 410,000 shares.","Murphy previously held leadership roles at Horizon Therapeutics, including Group VP Commercial Operations and Business Development.","THB335 IND-enabling toxicology studies nearing completion; pre-IND FDA interaction complete.","Company on track to file U.S. IND and initiate Phase 1 SAD/14-day MAD study in first half of 2024.","Cash and cash equivalents $273.9M as of Sept 30, 2023; strong financial position."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-001929","json":"https://secwatch.observer/filing/0001193125-24-001929.json","markdown":"https://secwatch.observer/filing/0001193125-24-001929.md","text":"https://secwatch.observer/filing/0001193125-24-001929.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1923840/000119312524001929/0001193125-24-001929-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1923840/000119312524001929/d107873d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:17:58.787851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a4a1bfb26d","claim":"Christopher M. Murphy was appointed as Chief Financial and Business Officer at Third Harmonic Bio, Inc..","evidence_excerpt":"On January 4, 2024, Third Harmonic Bio, Inc. (the “ Company ”), announced the appointment of Christopher M. Murphy, age 40, as the Company’s Chief Financial and Business Officer and principal financial officer, effective as of January 4, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1923840/000119312524001929/0001193125-24-001929-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial and Business Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}